Last updated: February 19, 2026
Exemestane, a steroidal aromatase inhibitor, is primarily used in hormone receptor-positive breast cancer treatment. It is marketed under the brand name Aromasin by Pfizer and has a well-established position in oncology.
The global exemestane market reached approximately USD 630 million in 2022. The compound's usage is concentrated in breast cancer therapy, particularly post-menopause. The growing prevalence of breast cancer and evolving treatment guidelines support ongoing demand.
Pfizer’s Aromasin holds the dominant market share. Several generic manufacturers have entered the space since patent expiry in 2018, intensifying price competition. Major competitors include Teva, Mylan, and Sun Pharmaceutical.
The wholesale acquisition cost (WAC) for brand-name exemestane in the US was approximately USD 10.50 per 25 mg tablet in 2022. Generic options are priced around USD 4–6 per tablet, reflecting significant reductions.
Prices are expected to decline modestly over the next decade owing to market saturation and manufacturing efficiencies.
Pfizer’s patent for Aromasin expired in 2018 for most markets. Some regions retain data exclusivity periods until 2022–2023, delaying generic entry. Regulatory approvals for generics are largely aligned with US FDA and EMA standards.
The global exemestane market is expected to grow at a compound annual growth rate (CAGR) of approximately 4% from 2023 to 2030. Price declines are projected to continue slowly, with US prices stabilizing around USD 3–4 per tablet by 2030.
1. How does the patent status affect exemestane pricing? Patent expiry in 2018 allowed generic manufacturers to enter the market, leading to significant price reductions and increased competition.
2. What factors influence the growth of exemestane in emerging markets? Rising breast cancer rates, expanding healthcare access, and increasing awareness drive growth. Regulatory approvals and price affordability also play roles.
3. Are biosimilars expected for exemestane? No. Exemestane is a small-molecule drug, not a biologic, thus biosimilars are not applicable. Generics serve as the primary competitive alternative.
4. What is the average wholesale price for exemestane? In the US, approximately USD 4.50 per 25 mg tablet for generics as of 2022.
5. How does exemestane compare with other aromatase inhibitors? It is similar in efficacy but has a unique steroidal mechanism. Cost and patent status differentiate it from non-steroidal alternatives like letrozole and anastrozole.
[1] World Health Organization. (2021). Global Cancer Statistics. WHO.
[2] IQVIA. (2022). Global Oncology Drug Market Review.
[3] Pfizer. (2022). Aromasin (Exemestane) Prescribing Information.
[4] European Medicines Agency. (2022). Regulatory Status of Exemestane.
[5] US Food and Drug Administration. (2022). Market Exclusivity and Patent Data for Exemestane.
